PSGL-1/SLeX/IL-10 MSCs display improved antiinflammatory impact in vivo via targeted delivery of IL-10 to the inflamed site. (A) Triple transfected PSGL-1/SLeX/IL-10 MSCs exhibit an antiinflammatory effect in vivo demonstrated via ear thickness measurements. Data are presented as decrease in inflamed ear thickness (after treatment with the different MSC groups) in comparison with control group (mice receiving saline treatment). *P < .05, 1-way ANOVA using Tukey’s HSD; error bars represent SEM) (n = 5 per group). (B) Only triple-transfected MSCs deliver a significant amount of IL-10 to the inflamed ear. At the specified time points following MSC transplantation, mice were sacrificed; ears were harvested and analyzed for presence of human IL-10 using an ELISA assay. Each point in the graph represents data from a single mouse. *P < .05 vs all other groups at the same time point, 1-way ANOVA using Tukey’s HSD; error bars represent SD (n = 4 per group).